Luca Maria Sconfienza

Prof. Dr. Luca Maria Sconfienza

IRCCS Istituto Ortopedico Galeazzi, Via Riccardo Galeazzi 4, Dipartimento Sci Biomed Salute, Milan, Italy
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2019 in European Radiology
Verified
Journal Article
Closed access
PDF file
DADomenico Albano
Domenico Albano
CMCarmelo Messina
Carmelo Messina
Jacopo Antonino VitaleJacopo Antonino Vitale
Jacopo Antonino Vitale
LSLuca Maria Sconfienza
Luca Maria Sconfienza

6 June 2018 in European Radiology
Verified
Journal Article
Closed access
PDF file
LSLuca Maria Sconfienza
Luca Maria Sconfienza
DADomenico Albano
Domenico Albano
GAGeorgina Allen
Georgina Allen
ABAlberto Bazzocchi
Alberto Bazzocchi
BBBianca Bignotti
Bianca Bignotti
ATAlberto Stefano Tagliafico
Alberto Stefano Tagliafico

23 October 2021 in Abdominal Radiology
Verified
Journal Article
Open access
PDF file
Vito ChiancaVito Chianca
Vito Chianca
Domenico AlbanoDomenico Albano
Domenico Albano
CMCarmelo Messina
Carmelo Messina
SGSalvatore Gitto
Salvatore Gitto
GRGaetano Ruffo
Gaetano Ruffo
LSLuca Maria Sconfienza
Luca Maria Sconfienza
Sarcopenia is a progressive, generalized skeletal muscle disorder characterized by reduction of muscle mass and strength. It is associated with increased adverse outcomes including falls, fractures, physical disability, and mortality, particularly, in elderly patients. Nowadays, sarcopenia has become a specific imaging biomarker able to predict clinical outcomes of patients. Muscle fibre reduction has shown to be an unfavourable pre-operative predictive factor in patients with cancer, and is associated with worse clinical outcomes in terms of postoperative complications, morbidity, mortality, and lower tolerance of chemoradiation therapy. Several imaging modalities, including dual-energy X-ray absorptiometry, CT, MRI, and US can be used to estimate muscle mass and quality to reach the diagnosis of sarcopenia. This article reviews the clinical implications of sarcopenia, how this condition can be assessed through different imaging modalities, and future perspectives of imaging of sarcopenia.

20 May 2009 in Gut
Verified
Journal Article
Open access
PDF file
ESEdoardo Vincenzo Savarino
Edoardo Vincenzo Savarino
DPD Pohl
D Pohl
PZPatrizia Zentilin
Patrizia Zentilin
PDP Dulbecco
P Dulbecco
GSG Sammito
G Sammito
VSV Savarino
V Savarino
Introduction: Functional dyspepsia and non-erosive reflux disease (NERD) are prevalent gastrointestinal conditions with accumulating evidence regarding an overlap between the two. Still, patients with NERD represent a very heterogeneous group and limited data on dyspeptic symptoms in various subgroups of NERD are available. Aim: To evaluate the prevalence of dyspeptic symptoms in patients with NERD subclassified by using 24 h impedance-pH monitoring (MII-pH). Methods: Patients with typical reflux symptoms and normal endoscopy underwent impedance-pH monitoring off proton pump inhibitor treatment. Oesophageal acid exposure time (AET), type of acid and non-acid reflux episodes, and symptom association probability (SAP) were calculated. A validated dyspepsia questionnaire was used to quantify dyspeptic symptoms prior to reflux monitoring. Results: Of 200 patients with NERD (105 female; median age, 48 years), 81 (41%) had an abnormal oesophageal AET (NERD pH-POS), 65 (32%) had normal oesophageal AET and positive SAP for acid and/or non-acid reflux (hypersensitive oesophagus), and 54 (27%) had normal oesophageal AET and negative SAP (functional heartburn). Patients with functional heartburn had more frequent (p<0.01) postprandial fullness, bloating, early satiety and nausea compared to patients with NERD pH-POS and hypersensitive oesophagus. Conclusion: The increased prevalence of dyspeptic symptoms in patients with functional heartburn reinforces the concept that functional gastrointestinal disorders extend beyond the boundaries suggested by the anatomical location of symptoms. This should be regarded as a further argument to test patients with symptoms of gastro-oesophageal reflux disease in order to separate patients with functional heartburn from patients with NERD in whom symptoms are associated with gastro-oesophageal reflux.

1 July 2009 in Radiology
Verified
Journal Article
Closed access
GSGiovanni Serafini
Giovanni Serafini
LSLuca Maria Sconfienza
Luca Maria Sconfienza
FLFrancesca Lacelli
Francesca Lacelli
ESEnzo Silvestri
Enzo Silvestri
AAAlberto Aliprandi
Alberto Aliprandi
FSFrancesco Sardanelli
Francesco Sardanelli
Purpose: To compare short- and long-term outcomes of patients with rotator cuff calcific tendonitis who did and did not undergo ultrasonographically (US)-guided percutaneous treatment. Materials and Methods: Institutional review board approval and informed patient consent were obtained. Of patients referred for US-guided treatment of rotator cuff calcific tendonitis, 219 (86 men, 133 women; mean age, 40.3 years ± 10.9 [standard deviation]) were treated; 68 (31 men, 37 women; mean age, 40.2 years ± 11.3) patients refused treatment and served as control subjects. After local anesthesia was induced, two 16-gauge needles were inserted into the calcific deposit. Saline solution was injected through one needle, and the dissolved calcium was extracted through the other needle. Shoulder joint function was assessed by using Constant scores, and pain was assessed by using visual analogue scale (VAS) scores. Mann-Whitney U and χ2 tests were performed. Results: At baseline, no significant difference in age or sex dis...

1 January 2019 in International Journal of Hyperthermia
Verified
Journal Article
Open access
EPEnrico Papini
Enrico Papini
CPClaudio Maurizio Pacella
Claudio Maurizio Pacella
Luigi Alessandro SolbiatiLuigi Alessandro Solbiati
Luigi Alessandro Solbiati
GAGaetano Achille
Gaetano Achille
DBDaniele Barbaro
Daniele Barbaro
Giovanni MauriGiovanni Mauri
Giovanni Mauri
Benign thyroid nodules are a common clinical occurrence and usually do not require treatment unless symptomatic. During the last years, ultrasound-guided minimally invasive treatments (MIT) gained an increasing role in the management of nodules causing local symptoms. In February 2018, the Italian MIT Thyroid Group was founded to create a permanent cooperation between Italian and international physicians dedicated to clinical research and assistance on MIT for thyroid nodules. The group drafted this list of statements based on literature review and consensus opinion of interdisciplinary experts to facilitate the diffusion and the appropriate use of MIT of thyroid nodules in clinical practice. (#1) Predominantly cystic/cystic symptomatic nodules should first undergo US-guided aspiration; ethanol injection should be performed if relapsing (level of evidence [LoE]: ethanol is superior to simple aspiration = 2); (#2) In symptomatic cystic nodules, thermal ablation is an option when symptoms persist after ethanol ablation (LoE = 4); (#3) Double cytological benignity confirmation is needed before thermal ablation (LoE = 2); (#4) Single cytological sample is adequate in ultrasound low risk (EU-TIRADS ≤3) and in autonomously functioning nodules (LoE = 2); (#5) Thermal ablation may be proposed as first-line treatment for solid, symptomatic, nonfunctioning, benign nodules (LoE = 2); (#6) Thermal ablation may be used for dominant lesions in nonfunctioning multinodular goiter in patients refusing/not eligible for surgery (LoE = 5); (#7) Clinical and ultrasound follow-up is appropriate after thermal ablation (LoE = 2); (#8) Nodule re-treatment can be considered when symptoms relapse or partially resolve (LoE = 2); (#9) In case of nodule regrowth, a new cytological assessment is suggested before second ablation (LoE = 5); (#10) Thermal ablation is an option for autonomously functioning nodules in patients refusing/not eligible for radioiodine or surgery (LoE = 2); (#11) Small autonomously functioning nodules can be treated with thermal ablation when thyroid tissue sparing is a priority and ≥80% nodule volume ablation is expected (LoE = 3).